Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxychloroquine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 known ✓ | Q9NR96 | 1/20 | 1.00 |
| ▸ | TLR7 known ✓ | Q9NYK1 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 1.00 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 1.00 |
| ▸ | CGAS | Q8N884 | 1/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.86 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.86 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydroxychloroquine SCHEMBL31023589 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29430237 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL9047 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL30107680 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL6746375 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL8623049 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL29359553 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL23854335 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL4204503 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 | |
| Hydroxychloroquine SCHEMBL4742350 | 0.99 | CHRM2 (0.98) | CHRM2CHRM4CHRM5ADRA2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46701 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081397-A | Application of hydroxychloroquine in improving gene editing efficiency | — | 2026-05-26 | — | — | CN | claimed |
| CN-122095104-A | Biomarkers for Systemic Lupus Erythematosus (SLE) disease activity immune index characterizing disease activity | — | 2026-05-26 | — | — | CN | claimed |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | EXAGEN INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260141455-A1 | LOCATION BASED DATABASE SYSTEM DASHBOARDS | EXPRESS SCRIPTS STRATEGIC DEV INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026107085-A1 | METHODS OF TREATING LUPUS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-1991011183-A1 | INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS -1 INFECTIVITY IN HUMAN CELLS | US COMMERCE (US) | 1991-08-08 | — | — | WO | claimed |
| US-4996047-A | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1991-02-26 | — | — | US | claimed |
| EP-0367746-A2 | Sustained release drug-resin complexes | RICHARDSON-VICKS, INC. (US) | 1990-05-09 | — | — | EP | claimed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | claimed |
| EP-0331471-A1 | High molecular weight prodrug derivatives of antiinflammatory drugs | Larsen, Claus Selch (DK) | 1989-09-06 | — | — | EP | claimed |
| EP-0037175-B1 | PHARMACEUTICAL COMPOSITIONS | EFAMOL LIMITED (GB) | 1988-02-10 | — | — | EP | claimed |
| EP-0035856-B1 | PHARMACEUTICAL AND DIETARY COMPOSITIONS | EFAMOL LIMITED (GB) | 1984-07-04 | — | — | EP | claimed |
| EP-0037175-A1 | Pharmaceutical compositions | EFAMOL LIMITED (GB) | 1981-10-07 | — | — | EP | claimed |
| EP-0035856-A2 | Pharmaceutical and dietary compositions | EFAMOL LIMITED (GB) | 1981-09-16 | — | — | EP | claimed |
| US-4181725-A | BROMOPHENACYL BROMIDE, TOCOPHEROL, MEPACRINE, (HYDROXY)CHLOROQUINE, DIBUCAINE, TETRACAINE, LIDOCAINE, BUTACAINE, PROCAINE, EDTA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1980-01-01 | — | — | US | claimed |